94278-70-3

Usage

Uses

Used in Pharmaceutical Synthesis:
2-(bromomethyl)-1,3-dichloro-5-methoxybenzene is used as a chemical intermediate for the synthesis of pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its unique structure allows for further chemical reactions to produce a variety of medicinal compounds.
Used in Agrochemical Production:
In the agrochemical industry, 2-(bromomethyl)-1,3-dichloro-5-methoxybenzene is utilized as a precursor in the production of various agrochemicals, such as pesticides and herbicides. Its presence in these compounds can enhance their effectiveness in controlling pests and weeds in agricultural settings.
Used in Organic Reactions:
2-(bromomethyl)-1,3-dichloro-5-methoxybenzene serves as a building block in various organic reactions, enabling the formation of more complex molecules with diverse applications. Its reactivity and functional groups make it a valuable component in organic synthesis.
Safety Precautions:
It is crucial to handle 2-(bromomethyl)-1,3-dichloro-5-methoxybenzene with care, as it is a toxic compound. Exposure may cause irritation to the skin, eyes, and respiratory system. Proper safety measures, including the use of personal protective equipment and adherence to safety protocols, should be taken to minimize risks associated with its use.

Upstream product

• 60964-09-2 2,6-dichloro-4-hydroxybenzaldehyde 
• 82772-93-8 2,6-dichloro-4-methoxy-benzaldehyde 
• 461031-79-8 4-(benzyloxy)-2,6-dichlorobenzaldehyde 
• 126663-61-4 1-<(tert-butyldimethylsilyl)oxy>-3,5-dichlorobenzene 
• 591-35-5 3,5-dichlorophenol 
• 94278-65-6 methyl 2,6-dichloro-4-methoxybenzoate 

Downstream Products

• 956125-91-0 (R)-4-benzyl-3-[(S)-2-(4-methoxy-2,6-dichloro-benzyl)-pent-4-enoyl]-oxazolidin-2-one 
• 956319-21-4 2-(2,6-dichloro-4-methoxy-benzyl)-isoindole-1,3-dione 
• 956125-88-5 (R)-4-benzyl-3-[(S)-2-(4-methoxy-2,6-dichloro-benzyl)-pent-4-enoyl]-oxazolidin-2-one 
• 911724-17-9 3-(2,6-dichloro-4-methoxy-benzyl)-1-(1,4-dioxa-spiro[4.5]dec-8-yl)-pyrrolidin-2-one 
• 956319-22-5 2,6-dichloro-4-methoxy-benzylamine hydrochloride 
• 955406-96-9 3-[2,6-Dichloro-4-(1-methyl-1H-pyrazol-4-yl)-benzyl]-1-(4,5,6,7-tetrahydro-2H-indazol-5-yl)-pyrrolidin-2-one 
• 955407-60-0 3,5-Dichloro-N-isobutyl-4-[2-oxo-1-(4,5,6,7-tetrahydro-2H-indazol-5-yl)-pyrrolidin-3-ylmethyl]-benzamide 
• 955406-24-3 C₂₇H₂₄Cl₂F₃N₃O₅S 
• 956125-90-9 (R)-3-(2,6-dichloro-4-methoxy-benzyl)-1-piperidin-1-yl-pyrrolidin-2-one hydrochloride 
• 956125-95-4 (R)-3',5'-dichloro-4'-(2-oxo-1-piperidin-1-yl-pyrrolidin-3-ylmethyl)-biphenyl-4-carboxylic acid 
• 956125-94-3 (R)-3',5'-dichloro-4'-(2-oxo-1-piperidin-1-yl-pyrrolidin-3-ylmethyl)-biphenyl-4-carboxylic acid methyl ester 
• 956125-93-2 (R)-trifluoro-methanesulfonic acid 3,5-dichloro-4-(2-oxo-1-piperidin-1-yl-pyrrolidin-3-ylmethyl)-phenyl ester 
• 956125-92-1 (R)-3-(2,6-dichloro-4-hydroxy-benzyl)-1-piperidin-1-yl-pyrrolidin-2-one 
• 956125-89-6 (R)-4-((R)-benzyl-2-oxo-oxazolidin-3-yl)-3-(4-methoxy-2,6-dichloro-benzyl)-4-oxo-butyraldehyde 

Relevant academic research and scientific papers

NOVEL COMPOUNDS

Described herein are compounds that are inhibitors of p21-activated kinases (PAKS). In particular, the compounds described herein are demonstrated to be selective PAK4 inhibitors. The compounds described herein are also demonstrated to reduce the expression of key immune checkpoint molecules, such as PD-1 and CHEK2. Also described herein are pharmaceutical compositions containing such compounds, methods for using such compounds in the treatment of cancers, more specifically, the treatment of pancreatic and lung cancers, and to related uses.

CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

The present invention discloses novel compounds of Formula (I): having 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compound

CYCLOHEXYLIMIDAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

The present invention discloses novel compounds of Formula I: ( I ) having 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds

SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

The present invention discloses novel compounds of Formula I: ( I ) possessing 11β -HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11 β -HSD type 1 activity.

INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

The present invention discloses novel compounds of Formula I: having 11 Beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11Beta-HSD type 1 activity. X-17377

INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

The present invention discloses novel compounds of Formula I: ( I ) possessing 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11β-HSD type 1 activity.

PIERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

ABSTRACT The present invention discloses novel compounds of Formula I: ( I ) having 11-Beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11-Beta-HSD type 1 activity. X-17433 PCT -1-

INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

The present invention discloses novel compounds of Formula I: (I) having 11 -HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11 -HSD type 1 activity.